

Rational Design of Safer Inorganic Nanoparticles via Mechanistic Modeling-Informed Machine Learning

Joseph Cave, Anne Christiano, Carmine Schiavone, Henry J. Pownall, Vittorio Cristini, Daniela I. Staquicini, Renata Pasqualini, Wadih Arap, C. Jeffrey Brinker, Matthew Campen, Zhihui Wang, Hien Van Nguyen, Achraf Noureddine, and Prashant Dogra*



Cite This: *ACS Nano* 2025, 19, 21538–21555



Read Online

ACCESS |


Metrics & More

Article Recommendations

Supporting Information

ABSTRACT: The safety of inorganic nanoparticles (NPs) remains a critical challenge for their clinical translation. To address this, we developed a machine learning (ML) framework that predicts NP toxicity both *in vitro* and *in vivo*, leveraging physicochemical properties and experimental conditions. A curated *in vitro* cytotoxicity dataset was used to train and validate binary classification models, with top-performing models undergoing explainability analysis to identify key determinants of toxicity and establish structure-toxicity relationships. External testing with diverse inorganic NPs validated the predictive accuracy of the framework for *in vitro* settings. To enable organ-specific toxicity predictions *in vivo*, we integrated a physiologically based pharmacokinetic (PBPK) model into the ML pipeline to quantify NP exposure across organs. Retraining the ML models with PBPK-derived exposure metrics yielded robust predictions of organ-specific nanotoxicity, further validating the framework. This PBPK-informed ML approach can thus serve as a potential alternative approach to streamline NP safety assessment, enabling the rational design of safer NPs and expediting their clinical translation.

KEYWORDS: nanoparticle, cytotoxicity, mathematical modeling, machine learning, artificial intelligence, PBPK, nanotoxicity



INTRODUCTION

Inorganic nanoparticles (NPs) have emerged as versatile platforms in biomedical applications, offering unparalleled tunability and precise control over physicochemical properties, including size, morphology, zeta (ζ) potential, surface coating, surface chemistry, and core composition.¹ This flexibility underpins the design of next-generation inorganic NPs with advanced drug delivery capabilities,² such as superior drug encapsulation,³ enhanced colloidal stability,⁴ targeted delivery,⁵ controlled release,⁶ and stimuli-responsive release.⁷ Beyond drug delivery, inorganic NPs enable a diverse range of applications, including bioimaging,^{8–10} antimicrobial therapy,¹¹ photodynamic therapy,¹² biosensing,¹³ enzyme-mimicking catalysis,¹⁴ and theranostics.^{15,16}

Despite these promising features, translating inorganic NP technologies to clinical practice remains a formidable challenge.¹⁷ A critical hurdle is the control of nano-bio interactions,¹⁸ such as protein corona formation, opsonization, and immune cell recognition, which often trigger rapid sequestration of NPs by the mononuclear phagocytic system (MPS), primarily the liver and spleen.^{19,20} This early clearance


diminishes NP accumulation at target sites^{21,22} while increasing the risk of off-target toxicity.^{23–25} Additionally, the delayed degradation of inorganic NPs and the potential toxicity of their degradation products pose significant long-term safety concerns.²⁶ Nano-bio interactions, along with the resulting exposure and toxicity profiles, are heavily influenced by the physicochemical properties of NPs, offering opportunities for rational design to optimize the *in vivo* disposition and safety. For instance, physicochemical attributes such as particle size, ζ -potential, surface coating, and core composition dictate circulation half-life,²⁷ biodistribution,²⁸ and toxicity.^{29,30} Typically, smaller NPs persist longer in circulation, exposing unintended organs like the kidneys, while larger particles are rapidly sequestered by the MPS.³¹ Such off-target accumu-

Received: February 27, 2025

Revised: May 15, 2025

Accepted: May 16, 2025

Published: June 3, 2025






Figure 1. *In vitro* nanotoxicity prediction pipeline, dataset characterization, and machine learning (ML) model testing. (a) The workflow for *in vitro* cytotoxicity predictions begins with data collection, resulting in a curated dataset of 8190 samples. Data preprocessing includes harmonization of physicochemical descriptors, toxicity classification, scaling, and one-hot encoding for ML model training and testing. The dataset is split into 80% training and 20% test subsets, with a nested cross-validation (nCV) framework applied to the training set. Internal testing is performed on the reserved test subset. Explainability analyses are employed to identify key toxicity drivers. External testing is performed by using in-house experimental data based on mesoporous silica nanoparticles (MSNs) and additional curated data from the S²NANO repository. (b) Dataset description and feature distributions. (i) Data inclusion criteria focus on studies reporting complete descriptors for inorganic NPs, including physicochemical properties, experimental conditions, and cell viability as a toxicity end point. (ii) Distribution of the target variable shows that 37.3% of samples were classified as cytotoxic, while 62.7% were nontoxic. (iii) Continuous input features include particle size, administered concentration, and exposure time, showcasing the wide variability in experimental conditions. (iv) Categorical input features include NP composition, surface coatings, ζ -potential, shape, cell class (primary or cell lines), and target organ. (c) Internal testing results. Precision-recall (PR) curves demonstrate the performance of top ML models, including CatBoost, gradient boosting classifier (GBC), random forest (RF), extra trees, and LightGBM. The inset receiver operating characteristic (ROC) curve shows true positive rates (TPR) versus false positive rates (FPR). Dashed black line in PR curve plot denotes the baseline precision for random guessing, while in the ROC curve plot it represents random classifier performance (FPR = TPR). (d) Heatmap summarizing key testing metrics (PR-AUC, ROC-AUC, recall, and precision) for the best-performing models, highlighting the strong predictive capabilities of boosting and tree-based algorithms.

lation can induce localized reactive oxygen species (ROS) generation,³² causing oxidative stress and disrupting many cellular processes through DNA damage,³³ membrane disruption,³⁴ and apoptosis.³⁵ Moreover, charged NPs can amplify interactions with immune cells, further exacerbating inflammation and safety concerns.³⁶

Addressing these challenges requires predictive tools that quantitatively link NP properties to toxicity outcomes, thereby facilitating the rational design of safer NPs for clinical

applications. Although traditional quantitative structure–activity relationship (QSAR) models have proven successful for small molecules, they face significant limitations when applied to nanomaterials due to their unique physicochemical properties and complex nano-bio interactions. Early attempts at applying QSAR to metallic and metal oxide NPs incorporated molecular-level descriptors such as electronegativity and oxidation state but largely overlooked size-dependent phenomena and surface effects critical at the

nanoscale.³⁷ This mismatch underscores the urgent need for nanospecific approaches that accommodate the surface characteristics, size, and the dynamic interactions distinguishing NPs from small molecules.

Machine learning (ML) has emerged as a powerful alternative, leveraging nano-relevant descriptors to improve toxicity predictions. Studies have demonstrated its utility across various NP systems. For instance, CatBoost models identified concentration, hydrodynamic size, and exposure time as key predictors for silica NP cytotoxicity,³⁸ while decision tree classifiers emphasized material chemistry, ζ -potential, and NP size for broader NP types.³⁹ Random forest models have similarly revealed composition, ζ -potential, and exposure time as critical toxicity determinants.⁴⁰ These findings underscore the power of ML to integrate physicochemical and experimental parameters for robust *in vitro* predictions; however, many studies remain limited to single end points or specific NP types.

Expanding on cytotoxicity-focused models, studies have employed ML frameworks to address more complex toxicity end points and systemic interactions. For example, ML models have been used to assess pulmonary immune responses and NP lung burden, identifying parameters such as surface area, dose, and size as significant predictors.⁴¹ Tree-based models have highlighted core type, size, and surface coatings for human lung cytotoxicity,⁴² while *in vitro* studies in cells have found cell line, dose, and tissue as major toxicity determinants.⁴³ These efforts demonstrate the adaptability of ML to diverse toxicity contexts, although gaps remain in integrating dynamic *in vivo* processes.

Beyond the ML strategies discussed above, other modeling frameworks have also been developed to predict NP toxicity. For instance, multitasking models based on moving average techniques have been proposed to integrate diverse NP types, multiple toxicity end points, and contextual information such as confidence in experimental or theoretical conditions.^{44–46} Additionally, graph-based molecular representations (e.g., SMILES codes) combined with Monte Carlo optimization have shown promising results, particularly through open-source tools like CORAL.^{47,48} Software such as QSAR_Co^{49,50} offers further flexibility for generating quantitative structure-toxicity relationships using accessible, descriptor-driven workflows.

In parallel, emerging approaches incorporating omics data and advanced descriptors offer deeper insights into nano-bio interactions. For example, Bayesian networks with transcriptomics data have revealed disruptions in DNA damage and cell cycle regulation,⁵¹ while studies on silver⁵² and zinc⁵³ oxide NPs highlight exposure duration, ζ -potential, and surface coatings as critical toxicity drivers. ML models integrated with omics data have leveraged the use of nanoscale and molecular descriptors, including lysosomal dissociation degree, ζ -potential, and particle size, to predict immune cell toxicity.⁵⁴ Advanced algorithms, such as neural networks, have further refined predictions, capturing intricate interactions between NP properties and biological systems.⁵⁵

Despite these advances, current ML-based NP toxicity models are frequently constrained by limited data, narrow descriptor coverage, and a focus on specific NP types, reducing their applicability. Additionally, their inability to account for organ-specific *in vivo* exposure diminishes their translational relevance. To address these challenges, we assembled diverse descriptors spanning physicochemical properties, testing

conditions, and biological contexts to predict the cytotoxicity of inorganic NPs. To our knowledge, this study encompasses the largest curated database to date and introduces a novel binary classification framework integrating ML and physiologically based pharmacokinetic (PBPK) modeling to predict nanotoxicity under both *in vitro* and *in vivo* conditions. Through explainability analysis and external testing on diverse inorganic NPs, this framework uncovers hierarchies of toxicity determinants and quantitative structure-toxicity relationships. By experimentally verifying our predictions using both newly generated mesoporous silica NP data in primary and established cell lines, along with curated *in vitro* datasets from the S²NANO repository, we enhance model generalizability, bridging the gap between computational forecasts and real-world outcomes. This standardized novel alternative method (NAM)⁵⁶ offers a transformative approach to inorganic NP safety-by-design, accelerating clinical translation and regulatory approval of next-generation nanomaterials.

RESULTS AND DISCUSSION

ML Workflow and Data Curation for *In Vitro* Nanotoxicity Predictions. To address the need for robust predictive frameworks, we developed a computational workflow that integrates advanced ML tools for nanotoxicity prediction and curated a diverse dataset of inorganic NP cytotoxicity. The workflow outlined in Figure 1a bridges data curation and computational modeling, starting with dataset harmonization and progressing through binary classification model training and testing. Explainability analyses were conducted to uncover key toxicity determinants, and external testing, leveraging in-house experimental data and the Safe and Sustainable Nanotechnology repository (S²NANO; www.s2nano.org), assessed model performance and generalizability. This integrative framework establishes a robust pipeline for predicting *in vitro* NP cytotoxicity, bridging computational predictions with experimental testing and advancing safety-by-design efforts for inorganic NPs.

The curated dataset comprises 8190 samples extracted from 425 studies published between January 2004 and December 2023. These studies identified through systematic searches and prior meta-analyses,^{38,39,51–53,57} targeted *in vitro* toxicity of inorganic NPs in mammalian cell lines. Inclusion criteria focused on studies reporting essential descriptors, such as NP size, composition, concentration, surface coating, shape, ζ -potential, exposure time, and toxicity outcomes, quantified via cell viability (Figure 1b(i)).

The final dataset represents one of the most comprehensive collections for NP cytotoxicity studies, integrating diverse compositions, physicochemical properties, and experimental configurations (Figure 1b(iii–iv)). Particle sizes spanned 1.5 to 1,000 nm, with SiO₂ (41.1%), Ag (22.69%), and ZnO (14.51%) being the most common compositions. Surface coatings were predominantly unmodified (74.57%), while spherical geometries dominated (89.62%). ζ -potential, critical for assessing colloidal stability and biocompatibility, was reported as negative for 43.15% of NPs, neutral for 5.89%, and undetermined for 42.8%, reflecting data gaps. To preserve model robustness and avoid introducing a noninformative category, samples with undetermined ζ -potential were retained, and missing values were encoded by setting all three one-hot encoded binary features (positive, neutral, negative) to zero. Experimental configurations varied widely, with exposure durations spanning 0.083 to 336 h and




Figure 2. Explainability analysis, feature reduction, and internal testing of the reduced-feature models. (a) SHapley Additive exPlanations (SHAP) analysis for CatBoost, visualized as a beeswarm plot. Each point represents an individual prediction, highlighting the direction and magnitude of each feature's contribution to NP toxicity classification. Higher SHAP values indicate greater importance, with features like concentration, composition, and particle size emerging as the most influential determinants of toxicity. (b) SHAP consensus rankings across the top-performing models (CatBoost, GBC, RF, extra trees, LightGBM). The heatmap highlights high inter-model agreement, with concentration, composition, and particle size consistently ranked as the top three predictors. (c) Iterative feature reduction results for CatBoost, visualizing changes in PR-AUC (i), ROC-AUC (ii), recall (iii), and precision (iv) as features are added in descending order of SHAP importance. The dashed black line denotes the point of performance saturation, beyond which adding additional features provides minimal improvement in predictive performance. (d) Internal testing of top-performing models using the reduced-feature set, evaluated through PR curves and ROC curves. The PR curves demonstrate strong predictive power with minimal loss compared to full-feature models, while the inset highlights ROC curves for these models. Dashed black line in PR curve plot denotes the baseline precision for random guessing, while in ROC curve plot, it represents random classifier performance ($FPR = TPR$). (e) Performance heatmap summarizing internal testing metrics (PR-AUC, ROC-AUC, recall, precision) for top-performing models with reduced features.

administered concentrations from 5×10^{-4} to $3.2 \times 10^6 \mu\text{g mL}^{-1}$. Human-derived cells accounted for 75.27% of samples, with lungs (18.71%), skin (8.79%), and blood (8.33%) being

the most studied organs, reflecting their relevance to primary exposure routes and systemic distribution. Harmonization aligned features across datasets, enabling consistent toxicity

classification based on ISO 10993–5 standards (see **Methods**). Using the 70% viability threshold,³⁸ 62.74% of samples were classified as nontoxic and the remaining as toxic, indicating a moderate class imbalance (**Figure 1b(ii)**). Although we did not evaluate alternative thresholds in this study, we acknowledge that predictions for samples near the 70% cutoff may be more sensitive to threshold selection. Future work may explore threshold sensitivity or continuous modeling of the viability to capture more nuanced toxicity effects.

Boosting and Tree-Based Models: Optimal Tools for Nanotoxicity Prediction. Building on the diversity of the curated dataset and comprehensive descriptor coverage, we systematically explored its potential for cytotoxicity classification using advanced ML approaches. A total of 18 algorithms were evaluated within a robust 10-fold nested cross-validation (nCV) framework (**Figure 1a**), enabling precise hyperparameter tuning (**Table S1**) and effective overfitting control via early stopping where applicable (**Figure S2**). Generalizability was assessed using a reserved 20% test subset, ensuring an unbiased performance evaluation.

Given the class imbalance inherent in our dataset and the elevated cost of false negatives, we prioritized the precision-recall area under the curve (PR-AUC) and recall metrics over the receiver operating characteristic area under the curve (ROC-AUC) during evaluation. While ROC-AUC provides a general measure of classification performance, it often overestimates model capability in imbalanced scenarios.^{58,59} PR-AUC and recall better capture the ability of a model to identify toxic NPs while minimizing the risk of misclassification. Moreover, while PR-AUC is a comprehensive metric across thresholds, recall is particularly critical for high-stakes applications such as nanotoxicity predictions, where minimizing false negatives is vital to avoid underestimating potential risks. This emphasis on recall shaped our model selection, as models with slightly lower PR-AUC but higher recall were prioritized to ensure sensitivity in detecting toxic NPs.

Among the tested algorithms, boosting and tree-based models emerged as the top performers, with superior PR-AUC values (0.8798–0.9098) and high recall rates (0.8164–0.8705) (**Figure 1c,d; Figure S3; Table S3**). The best-performing models included CatBoost (PR-AUC: 0.9098, recall: 0.8705), gradient boosting classifier (GBC) (PR-AUC: 0.9079, recall: 0.8607), random forest (RF) (PR-AUC: 0.8990, recall: 0.8164), extra trees (PR-AUC: 0.8911, Recall: 0.8197), and LightGBM (PR-AUC: 0.8798, recall: 0.8377) (**Figure 1d**). Despite its marginally lower PR-AUC, LightGBM was favored over XGBoost due to its superior recall, highlighting its sensitivity in identifying toxic NPs (**Table S3**).

Conversely, models such as support vector machines (SVM), clustering algorithms, linear models, Naïve–Bayes classifiers, and discriminant analysis exhibited poorer performance, characterized by higher false-negative and false positive rates (**Figures S2, S3; Table S3**). For example, SVC (PR-AUC: 0.8623, recall: 0.7918), LDA (PR-AUC: 0.7403, recall: 0.8246), and logistic regression (PR-AUC: 0.7501, recall: 0.8410) showed limited reliability, underscoring their unsuitability for high-sensitivity applications such as nanotoxicity predictions.

To evaluate whether artificial neural networks (ANNs) offer advantages over traditional models, we conducted a comparative analysis using our top-performing boosting and tree-based algorithms as benchmarks. An ANN optimized via the Keras-Tuner framework achieved a PR-AUC of 0.9011,

comparable to the best traditional models (**Figure S5; Table S3**). However, its recall (0.7902) lagged behind, resulting in a higher misclassification rate for the toxic NPs. While the ANN has predictive potential, its computational demands, reduced recall, and low interpretability limit its practicality for preclinical applications. Thus, boosting and tree-based models emerged as optimal choices for this task.

SHAP Analysis Reveals Concentration, Composition, and Size as Key Predictors of Toxicity. Boosting and tree-based models not only deliver superior sensitivity in detecting toxic NPs but also offer greater interpretability and computational efficiency, making them the preferred choices for scalable and explainable nanotoxicity predictions. However, understanding why these models make specific predictions is crucial for translating computational insights into actionable guidelines for NP safety-by-design. To this end, we employed SHAP (SHapley Additive exPlanations),⁶⁰ a widely adopted algorithm for feature attribution in ML, to quantify the relative importance of input features in predicting NP toxicity.

Using CatBoost, our best-performing model, we analyzed the relative feature influence on NP toxicity predictions through SHAP values. Concentration in culture media, NP composition, and particle size emerged as the top three predictors of cytotoxicity (**Figure 2a**). These features consistently ranked the highest across the top-performing models, highlighting their critical role in determining NP toxicity (**Figure 2b**). Secondary influential features, including target organ, exposure time, and surface coating, also contributed to predictive performance but to a lesser degree compared to the top three factors (**Figure 2a,b**).

In contrast, features such as animal species, ζ -potential, particle shape, and cell class had minimal influence, as reflected by low SHAP values (**Figure 2a,b**). While ζ -potential is widely recognized for its role in influencing colloidal stability, cellular uptake, and protein corona formation, its low ranking in our analysis may stem from several factors. Approximately 43% of entries in our dataset lack defined ζ -potential values (**Figure 1b(iv)**), limiting the ability of the model to extract meaningful patterns. Furthermore, ζ -potential alone may not fully capture the complexity of NP surface interactions, as suggested by prior studies highlighting surface charge density as a more reliable predictor of toxicity than ζ -potential alone.⁶¹ The diversity of surface modifications across our dataset may have also diminished the relative importance of ζ -potential, as other surface properties could play a more prominent role in specific NP subgroups. Similarly, although particle morphology is often considered a key determinant of toxicity due to its effects on circulation half-life, endocytosis, immune response, and cell membrane disruption,⁶² its reduced importance here can be attributed to the homogeneity of this feature in our dataset. With 89.62% of NPs being spherical (**Figure 1b(iv)**), compounded by our assumption of a spherical geometry when unspecified, this feature lacked sufficient variability to provide discriminative power. Importantly, this should not be interpreted as evidence that shape lacks biological relevance, but rather as a consequence of limited diversity. As more shape-diverse, well-characterized studies emerge, we anticipate that NP morphology will emerge as a more influential feature in future iterations of the model. Lastly, cell class (i.e., primary versus cell lines) exhibited minimal influence, likely due to the limited variability in cell type composition within the dataset. With 87% of the entries corresponding to immortalized cell lines and only 13% corresponding to primary cells (**Figure**




Figure 3. Feature-specific explainability analysis to inform NP safety-by-design strategies. (a–c) Partial dependence plots (PDPs) depict the marginal effects of continuous features—NP concentration (a), exposure time (b), and particle size (c)—on predicted toxicity probabilities, holding all other features constant. Black dots represent data points, solid blue lines indicate model fits, and red dashed lines denote 95% confidence intervals. Empirical functions are provided to describe the observed trends. (d–f) SHAP summary plots illustrate the contribution of categorical features—ζ-potential (d), NP composition (e), and surface coating (f)—to toxicity predictions. Positive SHAP values indicate an increased probability of cytotoxicity, whereas negative values suggest reduced toxicity.

1b(iv)), the predictive utility of this feature in distinguishing toxicity outcomes was diminished.

To validate the reliability of the SHAP-derived feature hierarchy, we extended the analysis to the remaining top-performing models (Figure 2b). The consensus of feature rankings was evaluated using the Spearman correlation coefficient, revealing strong alignment across models, with $R > 0.89$. CatBoost exhibited excellent agreement with gradient boosting classifier ($R = 0.9879$), LightGBM ($R = 0.9758$), and random forest ($R = 0.9515$), supporting the robustness of the derived rankings. However, extra trees showed moderate agreement ($R = 0.7818$) due to its greater emphasis on ζ-potential and lower prioritization of particle size. While this deviation highlights model-specific tendencies, the overall consistency reinforces the generalizability of the identified toxicity determinants.

This SHAP analysis not only elucidates the key drivers of NP toxicity but also provides actionable insights into the rational design of safer NPs. By focusing on key features such as composition and particle size, which indirectly influence exposure levels and cellular interactions, researchers can optimize NP formulations to minimize cytotoxicity and enhance their translational potential. Furthermore, SHAP-based feature rankings present an opportunity to streamline

predictive models by identifying and retaining only the most impactful features, reducing model complexity while maintaining accuracy.

SHAP-Guided Feature Reduction and Model Optimization. Building upon the SHAP analysis, we implemented an iterative retraining strategy to identify the minimal subset of features required for robust model performance. Features were progressively added to the top-performing models in descending order of SHAP importance, and changes in PR-AUC, ROC-AUC, recall, and precision were monitored at each step (Figure 2c). This process revealed a performance plateau in PR-AUC, ROC-AUC, and precision after the incorporation of eight features: NP concentration, composition, particle size, target organ, exposure time, surface coating, species, and ζ-potential. These features proved essential for maintaining a high predictive performance. In contrast, features such as shape and cell class demonstrated negligible impact, confirming their limited role in toxicity predictions.

Strategically reducing features enhances interpretability and computational efficiency while retaining predictive accuracy. The reduced-feature models achieved PR-AUC values above 0.8619 and recall exceeding 0.8098 across all top-performing algorithms (Figure 2d,e; Table S3). The ensemble model outperformed individual algorithms, achieving a PR-AUC of

0.9114 and a recall of 0.8410, demonstrating robust performance with reduced complexity. The ROC curves further validate the minimal performance loss, showing near-identical trends between the full-feature and reduced-feature models (inset of Figure 2d). This consistency underscores the effectiveness of SHAP-guided feature reduction in simplifying models without compromising their predictive power.

The streamlined models offer significant advantages for preclinical deployment by reducing computational demands and enhancing interpretability. Additionally, the reduced model minimizes the number of features required for experimental measurements. By prioritizing eight key features, the model enables researchers to streamline experimental workflows, reducing the need to collect data on low-impact features. This not only enhances the cost efficiency but also accelerates NP screening and design, making the model highly suitable for preclinical and translational applications. These findings highlight the practical utility of explainable AI in toxicity modeling, providing a scalable framework for NP safety evaluation and rational design.

Feature-Specific Insights Into Nanotoxicity: A Framework for Safety-by-Design. Building upon these insights, we leveraged the reduced features set to establish guidelines for safety-by-design. Using partial dependence plots (PDPs) and SHAP, we systematically analyzed how variations in the top-ranked features influence NP toxicity. Concentration of NPs in culture media demonstrated a strong positive correlation with toxicity, showing a sigmoidal relationship as identified through regression analysis (Figure 3a). The regression model indicates a rapid increase in toxicity probability at concentrations exceeding $10 \mu\text{g mL}^{-1}$, which saturates at higher values. Similarly, exposure time followed a sigmoidal relationship, with a rapid increase in toxicity probability observed within the first 50 h, followed by a gradual plateau around 100 h (Figure 3b). This trend suggests that toxic effects primarily manifest early during exposure, though some effects may persist over longer durations depending on experimental conditions.

Our findings also reveal that the probability of a toxic prediction decreases following a power-law decay with particle size, resulting in a linear trend when plotted against the log₁₀-transformed particle size (Figure 3c). This trend aligns with existing evidence that smaller NPs are more toxic due to their higher surface area-to-volume ratio. For example, Song et al. demonstrated that smaller TiO₂ NPs (~25 nm) induce significant ER stress and apoptosis in HepG2 cells, in contrast to larger NPs (~100 nm).⁶³ Similarly, Pan et al. found that 1.4 nm AuNPs exhibit heightened genotoxicity across cell types by interacting with the major groove of B-DNA, disrupting transcription, and initiating cell death within 12 h.⁶⁴

Further, positively charged NPs exhibited an increased propensity for toxic predictions compared to neutral or anionic counterparts, as shown by higher SHAP values for cationic particles (Figure 3d). This effect can be attributed to stronger electrostatic interactions with negatively charged cell membranes, enhancing cellular uptake⁶¹ or destabilizing cell membranes.⁶⁵ Once internalized, these NPs dysregulate intracellular processes, particularly within the mitochondrial electron transport chain and endoplasmic reticulum (ER), leading to oxidative stress, cellular damage, and genotoxic effects, including prolonged arrest in the G0/G1 phase.⁶⁶ This ζ -potential-toxicity relationship aligns with literature,⁶⁷ including Hühn et al.'s findings that 3T3 fibroblasts rapidly internalized cationic AuNPs, resulting in elevated ROS levels.⁶⁸

Additionally, the NP composition was also a critical determinant of toxicity (Figure 3e). Heavy metal-based NPs such as Cd, Cu, ZnO, Mn, Ni, and Ag exhibited higher SHAP values, indicating increased toxicity likelihood. In contrast, compositions like Ce, hydroxyapatite, Co, Al, and Fe were associated with greater safety. The release of toxic ions, modulated by microenvironmental factors like pH and ionic strength, underlies this trend. Toxic ions such as Ag⁺ cause direct cellular damage, while biologically essential ions like Fe²⁺ can be harmful at high concentrations.⁶⁶ These findings are consistent with Kobayashi et al., who evaluated the cytotoxic potential of 12 inorganic NPs and ranked Cd NPs as the most toxic.⁶⁹

Surface coatings further modulate toxicity outcomes, with certain coatings reducing toxicity by preventing ion release or altering surface charge (Figure 3f). For example, polyethylene glycol (PEG) coatings have been shown to improve colloidal stability and reduce cellular uptake, mitigating toxicity.⁷⁰ However, the large variability in SHAP values across surface coatings underscores the importance of considering interdependent factors, such as geometry and composition, which collectively influence properties such as colloidal stability, ion release, and cellular interactions.

To assess whether the model captured conditional dependencies between key design parameters, we conducted SHAP interaction analysis for particle size, concentration, and exposure time (Figure S6). These plots visualize how the contribution of one feature to predicted toxicity varies as a function of another. Off-diagonal plots represent pairwise interactions, while diagonal plots reflect only the main effects of each feature. Visual inspection revealed largely uniform SHAP value trends across the x -axis and minimal color-based stratification, indicating weak interaction effects between feature pairs. This suggests that feature contributions to toxicity are largely independent, potentially due to dataset limitations, such as uneven sampling of feature combinations or the dominance of additive effects in nanotoxicity biology. Practically, this outcome enhances interpretability and supports safety-by-design efforts that rely on the independent tuning of physicochemical properties. Nonetheless, these findings highlight the potential value of future studies designed to more explicitly probe conditional interactions.

While PDP and SHAP analyses elucidate the marginal effects of individual features on toxicity predictions, NP toxicity is inherently multifactorial. The nonlinear interactions between physicochemical properties (e.g., size, charge, composition, and coating) and testing conditions (e.g., concentration and exposure time) necessitate an ML model to accurately capture these dynamics. The integration of SHAP and PDP with ML enables both accurate predictions and interpretable insights, providing a robust framework for understanding and mitigating NP toxicity.

The large variability in SHAP values, particularly for NP coatings and composition, underscores the importance of considering the interdependence of physicochemical properties across heterogeneous experimental protocols.⁷¹ For instance, surface coatings modify surface charge,⁷² colloidal stability, and hydrodynamic size,⁶⁶ while geometry influences systemic half-life, organ bioaccumulation, and endocytosis mechanisms. Composition further affects surface chemistry and reactivity, including crystal structure, which can impact toxicity outcomes.⁷³




Figure 4. In vitro cytotoxicity data generation and external testing of ML model generalizability. (a) Overview of test data sources, comprising in-house cytotoxicity experiments ($N = 63$) and additional external testing data from the rigorously curated S²NANO repository ($N = 454$), resulting in a combined external dataset ($N = 517$) for testing. (b) Experimental workflow for in-house cytotoxicity studies: (i) MSN synthesis using sol-gel fabrication and subsequent functionalization with lipid or polyethylenimine (PEI) coatings; (ii) characterization of MSNs by hydrodynamic size and ζ -potential measurements; (iii) cell viability assays performed on human cell lines (REH, 42D, MR49F) using ATP-based luminescence readings following NP exposure; (iv) hemolysis assays involving red blood cell (RBC) isolation and NP exposure, with phosphate buffer saline (PBS, negative control) and distilled water (DI water, positive control) validating

Figure 4. continued

assay accuracy. (c) Dataset description: (i) distribution of categorical input features, including NP composition, surface coating, ζ -potential, species, and target organ; (ii) continuous feature distributions for particle size, concentration, and exposure time. (d) External testing results presented as PR and ROC curves for the top-performing models (CatBoost, gradient boosting classifier (GBC), random forest (RF), extra trees, LightGBM) and the ensemble model. The dashed black line in the PR curve plot denotes the baseline precision for random guessing, while in the ROC curve plot, it represents random classifier performance ($FPR = TPR$). (e) Performance heatmap summarizing metrics, including PR-AUC, ROC-AUC, recall, and precision, highlighting the robust external testing and generalizability of the ensemble model, which achieved high recall and overall strong predictive performance.

Thus, our guidelines necessitate a holistic approach to safety-by-design, as previously demonstrated by Wu et al., who showed a size-dependent toxicity relationship in ultrasmall superparamagnetic iron oxide NPs (USPIONS).⁷⁴ Their study showed USPIONS of 2.3 and 4.2 nm localized in lysosomes in cardiac tissue after IV administration in mice, releasing Fe^{2+} ions under acidic conditions. This release inversely correlated with NP size and catalyzed Fenton reactions, producing hydroxyl radicals ($\cdot OH$) that led to oxidative stress and acute cardiac failure. In contrast, larger USPIONS (9.4 nm) and Au and SiO_2 NPs did not exhibit toxic effects. These findings highlight how size interacts with composition and the biological microenvironment to determine toxicity, underscoring the multifactorial nature of NP safety. This example demonstrates why a holistic framework, integrating key physicochemical properties and testing conditions, is critical for designing NPs that balance safety and functionality.

External Testing of Predictive Models for *In Vitro* Cytotoxicity. Building on the feature-specific insights from the previous section, we evaluated the real-world utility of our ML framework in predicting NP toxicity. While the integration of SHAP and PDP analyses established a comprehensive safety-by-design framework, validating its generalizability across diverse datasets and experimental conditions remains essential. To address this, we performed external testing with in-house experimental data derived from cytotoxicity and hemolysis assays using mesoporous silica nanoparticles (MSNs). MSNs were specifically chosen due to their tunable physicochemical properties, which our team has extensive expertise in tailoring during synthesis.^{75–77} This allowed us to systematically generate a diverse set of well-characterized MSNs, encompassing variations in size, ζ -potential, shape, porosity, and surface functionalities (Table S4). These particles serve as an ideal model nanomaterial for robust experimental testing. The experimental workflow is depicted in Figure 4a,b, and detailed protocols are provided in Supplementary Methods S2.

To extend the scope of testing, we incorporated high-quality entries from the S²NANO repository. This rigorously curated database contains NPs of diverse compositions, exposure scenarios, and experimental conditions, enabling a broader assessment of the predictive capabilities of our framework. The merged dataset of 517 samples (63 in-house and 454 from S²NANO) reflects a balance between cytotoxic (32.9%) and nontoxic (67.1%) samples (Figure 4a). This balance ensures that model performance is evaluated across both high- and low-risk samples, simulating realistic testing conditions. Importantly, the dataset encompasses diverse NP compositions (ZnO , SiO_2 , TiO_2), surface coatings, and ζ -potential values, as well as a wide range of particle sizes, concentrations, and exposure times (Figure 4c).

The external testing results, as shown in Figure 4d,e, illustrate the predictive power of the ML models using both PR

and ROC curves. The models yielded robust predictive performance on the external dataset, with PR-AUC values ranging from 0.82 to 0.85 and recall values from 0.81 to 0.91 (Figure 4e, Table S3). Among the individual models, random forest (RF) emerged as the top performer, achieving a PR-AUC of 0.84 and a recall of 0.89, surpassing its internal testing metrics (recall: 0.84). In contrast, CatBoost, which excelled in internal testing, did not perform as well during external testing, achieving a PR-AUC of 0.82 and a recall of 0.85. These discrepancies highlight the importance of external testing in identifying models that generalize effectively beyond their training datasets.

ROC curves provided complementary insights into the classification capabilities of the models, balancing sensitivity (true positive rate) and specificity (false positive rate) (inset of Figure 4d). Across all models, ROC-AUC values remained consistently high, ranging from 0.89 to 0.9247. Among the individual models, RF also achieved the highest ROC-AUC of 0.9247, followed closely by CatBoost (ROC-AUC: 0.9214) and GBC (ROC-AUC: 0.9147). While LightGBM had a slightly lower performance with an ROC-AUC of 0.9010, all models exceeded 0.89, confirming their reliability in external testing scenarios (Figure 4e, Table S3).

To mitigate variability in individual model performance and reduce the dependency on any single algorithm, we integrated the top-performing models into a unified stacking ensemble. By leveraging the complementary strengths of each base model, the ensemble achieved superior overall performance, with a PR-AUC of 0.85, a recall of 0.91, and a ROC-AUC of 0.92 (Figure 4e, Table S3). While the ensemble underperformed in precision compared with CatBoost (0.73), GBC (0.72), RF (0.70), and LightGBM (0.71), it achieved the highest recall among all models. This trade-off reflects a deliberate prioritization of sensitivity over specificity, recognizing that in early-stage toxicity screening, false negatives pose a greater risk than false positives. Although a slight reduction in precision may lead to additional follow-up experiments for false positive hits, this is generally acceptable in preclinical safety assessment, where caution is warranted. By optimizing recall while maintaining competitive overall performance, the ensemble model ensures robust generalizability and addresses the limitations of individual models, particularly in high-stakes preclinical testing scenarios.

The robust performance of the ensemble model across diverse experimental conditions and NP compositions signifies a pivotal advancement in *in vitro* nanotoxicity prediction. By replacing traditional trial-and-error approaches with a data-driven framework, our methodology supports the rational design of safer and more effective nanomedicines. These findings highlight the potential for deploying ML-driven strategies in nanomedicine with far-reaching implications for both clinical translation and regulatory approval processes.




Figure 5. PBPK-ML framework for predicting in vivo nanotoxicity. (a) Overview of the PBPK-ML model integration pipeline. Data curation involved selecting 390 samples based on inclusion criteria, including NP composition, murine/rodent models, and time-series biodistribution data. Time-averaged NP concentrations derived from the PBPK model were incorporated into retrained ML models previously optimized for in vitro predictions. (b) Schematic of the minimal PBPK model, illustrating NP biodistribution across organs (plasma, spleen, liver, kidneys, lungs, and others) and clearance via feces and urine following intravenous (IV), subcutaneous (SC), oral (PO), or intraperitoneal (IP) administration. (c) In vivo dataset description: (i) toxicity outcomes, showing a majority (83.8%) with no observed toxicity; (ii) categorical input features, including NP composition, surface coating, ζ -potential, species, and target organs; (iii) Continuous input features, such as particle size, concentration, and exposure time. (d) Representative PBPK model concentration kinetics fits for gold nanorods (AuNR) with various surface coatings, showing excellent agreement with experimental data (Pearson correlation coefficients > 0.98). (e) Internal testing results for PBPK-ML models using PR and ROC curves, highlighting the performance of the top algorithms. Dashed black line in PR curve plot denotes the baseline precision for random guessing, while in ROC curve plot, it represents

Figure 5. continued

random classifier performance ($FPR = TPR$). (f) Performance heatmap showing key metrics (PR-AUC, ROC-AUC, recall, and precision) for individual models and the ensemble model. The ensemble model achieved the highest accuracy, with PR-AUC = 0.93 and recall = 1.00, demonstrating the robustness of the PBPK-ML framework for organ-specific nanotoxicity predictions.

Extending ML Frameworks to Predict *In Vivo* Nanotoxicity. Leveraging the strength of our *in vitro* ML framework, we extended its applicability to *in vivo* settings by retraining it on curated *in vivo* nanotoxicity data. This adaptation bridges the gap between *in vitro* studies and complex *in vivo* dynamics, capturing the influence of organ-specific exposure and nano-bio interactions on toxicity outcomes. To achieve this, we incorporated a PBPK modeling approach^{78–80} to quantify time-averaged NP concentrations in individual organs. PBPK modeling incorporates the transport phenomena associated with NP biodistribution and simulates physiologically meaningful whole-body concentration–time profiles (Figure 5b; eqs S1–S8, Supplementary Methods S3). This allowed us to capture the nuances of *in vivo* exposure across diverse experimental conditions and study designs. The resulting exposure metrics replaced the concentration feature used in the *in vitro* ML framework, enabling a seamless extension of the ML models to *in vivo* settings while maintaining their predictive robustness (Figure 5a). The PBPK model used for this purpose was designed as a fit-for-purpose minimal framework to extract interpretable exposure metrics across heterogeneous *in vivo* studies. While it does not explicitly model protein corona formation or immune responses, these complexities are indirectly reflected in the fitted concentration–time profiles. This design choice ensures broad applicability and empirical consistency rather than mechanistic prediction, aligning with the goal of generating reliable exposure inputs for ML-based toxicity modeling.

The minimal PBPK (mPBPK) model developed here, comprising six compartments (plasma, liver, spleen, lungs, kidneys, and others), successfully simulated NP biodistribution kinetics across diverse physicochemical and physiological conditions (Figure 5c). Physiological parameters were fixed *a priori* based on literature values^{81,82} (Table S5), while NP-specific parameters were estimated using nonlinear least-squares fitting (Table S6). Goodness-of-fit was assessed using the Pearson correlation coefficient, with most simulations achieving R values >0.9 (Figure 5d, Figure S7). The distribution of fitted parameters across species and studies is summarized in Figure S8. Time-averaged concentration of NPs across organs in the various studies estimated from the simulated concentration–time curves ($\bar{C}_i = \frac{\text{AUC}_i(0-t_{\text{tox}})}{t_{\text{tox}}}$; see Methods) ranged from 0.01 to 7185.65 $\mu\text{g mL}^{-1}$ (Figure 5c(iii)), capturing diverse exposure scenarios relevant to both acute and chronic toxicity assessments. This metric consolidates temporal dynamics into a single representative value, enabling direct comparisons across studies with varying exposure durations. The mPBPK model offers a computationally efficient and generalizable approach to quantify NP biodistribution, guiding preclinical NP design for enhanced safety.

Using a curated dataset of 390 samples derived from 35 studies (Figure 5c), detailed NP biodistribution data enabled the parametrization of the mPBPK model and the retraining of the ML framework. This dataset encompassed diverse physicochemical properties, including gold (42.8%), iron

oxide (23.1%), and silver (9.1%) NPs, with a range of surface modifications and organ-specific exposure patterns. The integration of PBPK-derived metrics enhanced the ability of the framework to predict organ-specific *in vivo* toxicity, as demonstrated by robust model performance (Figure 5e,f).

Individual models were characterized by strong testing performance with PR-AUC values ranging from 0.89 to 0.96 and recall values from 0.86 to 1.0 (Figure 5f, Table S3). Among these, GBC achieved the highest PR-AUC (0.96) with a recall of 0.98, while RF attained perfect recall (1.0) but a slightly lower PR-AUC (0.93) due to reduced precision. Extra trees balanced precision and recall effectively, with a PR-AUC of 0.93 and a recall of 0.86. The stacking ensemble strategy leveraged the strengths of individual models, achieving a robust PR-AUC of 0.93 and perfect recall (1.0), demonstrating its ability to enhance generalizability and mitigate biases in individual models.

Complementary ROC analysis (inset of Figure 5e) confirmed the high predictive reliability of the models. The stacking ensemble achieved an outstanding ROC-AUC of 0.99, indicating a near-optimal classification performance across all false positive rates. Similarly, RF matched the performance of the ensemble with an ROC-AUC of 0.99, while extra trees followed closely at 0.98. Both CatBoost and LightGBM demonstrated strong classification capabilities, achieving ROC-AUCs of 0.98 and 0.97, respectively. In contrast, GBC exhibited comparatively lower performance with an ROC-AUC of 0.82, reflecting variability in its reliability. Collectively, these results underscore the robustness of the ensemble approach, effectively combining the strengths of individual models for highly accurate and generalizable nanotoxicity predictions.

The consistent performance of the stacking ensemble across PR-AUC and ROC-AUC metrics underscores its suitability for *in vivo* toxicity predictions. By mitigating individual model biases, the ensemble enhances reliability and generalizability across diverse datasets. These findings emphasize the potential of the PBPK-ML framework to bridge *in vitro* and *in vivo* toxicity assessments, facilitating the clinical adoption of safer, design-optimized NPs while minimizing toxicity risks.

CONCLUSIONS

The clinical translation of inorganic NPs has been stymied by a lack of standardized frameworks to predict toxicity across diverse experimental settings. Conventional trial-and-error approaches, compounded by inconsistencies in data reporting, have limited progress in the design and deployment of safe and effective NPs. Addressing these challenges, we present a novel ML framework, enhanced by PBPK modeling, to predict NP toxicity both *in vitro* and *in vivo* with unprecedented precision and scalability.

Our ML framework, trained on the largest curated *in vitro* cytotoxicity dataset to date, achieved robust predictive performance, with ensemble models demonstrating PR-AUCs exceeding 0.89 and recalls above 0.9. SHAP-based explainability analyses revealed NP concentration as the dominant predictor of toxicity, while other physicochemical features such as composition and size provided critical design insights. These

findings informed safety-by-design principles, providing a quantitative foundation for rational NP development. The use of SHAP also enabled robust interpretability and guided model simplification by identifying the most impactful features, making the framework more amenable to preclinical deployment.

The integration of a PBPK model represents a significant step forward, enabling mechanistic insights into organ-specific NP biodistribution and its impact on toxicity. This mechanistic layer allowed for the generation of time-averaged exposure metrics, bridging *in vitro* predictions with the complexity of *in vivo* environments. Ensemble models retrained on curated *in vivo* datasets achieved outstanding predictive accuracy, with PR-AUCs and ROC-AUCs approaching optimal performance. This integration of mechanistic modeling and ML provides a scalable and physiologically meaningful approach to preclinical safety assessment.

While these advances represent a significant milestone, several limitations warrant consideration. The relatively small size of the *in vivo* dataset and variability in biodistribution reporting across studies posed challenges to the generalizability of the PBPK model. In addition to its small size, the *in vivo* dataset also exhibited significant heterogeneity across NP types, exposure routes, and experimental protocols. Despite this, the PBPK model achieved strong fits to most studies (Pearson $R > 0.9$), supporting its utility for extracting reliable exposure metrics. However, the variability in study design may affect the comparability of these metrics and, in turn, limit the generalizability of the ML predictions trained on them. Expanding and standardizing *in vivo* datasets will be essential for improving the robustness and translational value of the framework. The exclusive focus on inorganic NPs limits the applicability of the framework to organic or hybrid nanomaterials. Furthermore, the *in vitro* dataset primarily consisted of toxicity data from immortalized cell lines, reflecting the current landscape of publicly available nanotoxicology data. While this supports high-throughput screening, it may limit physiological relevance, and future work will aim to incorporate primary cell systems and more complex tissue models to improve translational validity. Additionally, while the current dataset spanned 21 inorganic NP compositions, the ability of the model to generalize to nanomaterials with physicochemical properties that are sparsely represented or entirely absent from training remains limited. Expanding the dataset to include a broader chemical space, alongside additional descriptors, will be critical for enhancing the robustness of the framework across the diverse landscape of inorganic nanomaterials. Furthermore, the minimal PBPK model does not yet account for more complex nano-bio interactions, such as immune responses or protein corona formation. These constraints underscore the need for further data curation and mechanistic model refinements to enhance the scope and accuracy of the framework.

Looking ahead, this PBPK-informed ML framework offers a potential Novel Alternative Method (NAM) for preclinical safety assessments, providing a harmonized and scalable approach for evaluating NP toxicity. Future work will focus on addressing data gaps, particularly in biodistribution reporting, and expanding the framework to include organic and hybrid nanomaterials. An important future extension will involve integrating multiobjective optimization to jointly minimize organ-specific toxicity while maximizing target-site exposure, enabling the rational design of NPs that are both

safer and more effective in delivery. By bridging computational insights with experimental testing, this framework establishes a blueprint for rational NP design, accelerating the development of safer and more effective nanomedicines.

METHODS

Data Collection, Curation, and Preprocessing for *In Vitro* Cytotoxicity Predictions. Our *in vitro* cytotoxicity dataset was assembled from previously published meta-analyses^{38,39,51–53,57} and a systematic review of peer-reviewed articles (January 2004–May 2024) identified through Google Scholar, PubMed, and Web of Science. Searches were performed using structured combinations of keywords related to NP-type, composition, physicochemical properties, toxicological end points, and experimental setup. Strict inclusion criteria were applied: (i) only inorganic NPs were considered; (ii) studies must provide NP size, exposure duration, and NP concentration data; (iii) the focus was on biomedical rather than environmental safety applications; (iv) experiments had to be conducted *in vitro* using mammalian cell lines; (v) cytotoxicity had to be quantified via percentage cell viability. We extracted viability data using WebPlotDigitizer (<https://automeris.io/>). To maximize transparency and reproducibility, the complete search strategy are curation workflow are detailed in *Supplementary Methods S1* and *Figure S1*. This process ultimately yielded 425 eligible studies comprising 8,190 individual data points (*Figure 1a*).

To ensure data harmonization, particle sizes were standardized to nanometers (nm), exposure durations to hours (h), and concentrations to micrograms per milliliter ($\mu\text{g mL}^{-1}$). For missing categorical variables, surface coating was labeled “Unmodified” and shape was labeled “Sphere” where not reported. ζ -potential was categorized as positive ($\zeta > 10 \text{ mV}$), negative ($\zeta < -10 \text{ mV}$), neutral ($-10 \text{ mV} \leq \zeta \leq 10 \text{ mV}$), or “not determined,” prioritizing measurements in deionized water (or culture media if water measurements were unavailable). Samples with undetermined ζ -potential were retained in the dataset. During one-hot encoding, these entries were represented by setting all three ζ -potential binary features (positive, neutral, and negative) to zero, rather than introducing a noninformative placeholder category. This approach preserved mechanistic interpretability and avoided introducing spurious model signals from missing data.

Following ISO 10993–5 guidelines, the cell viability end point was binarized such that $\geq 70\%$ viability was labeled “safe” (assigned 0), and lower viability was labeled “cytotoxic” (assigned 1).³⁸ This encoding was performed using Pandas (Python). Next, each continuous variable (particle size, concentration, and exposure time) underwent outlier detection using a $1.5\times$ interquartile range cutoff; flagged outliers were manually inspected and removed if deemed unreliable or nonsensical.

The resulting dataset was then shuffled to eliminate order bias and split into training (80%) and test (20%) subsets via `train_test_split()` in Scikit-Learn (v1.5.1). We applied a logarithmic transformation to each continuous variable to mitigate skewness and stabilize the variance. Categorical variables underwent one-hot encoding using Scikit-Learn, omitting the least frequent category to avoid collinearity (i.e., the “dummy variable trap”; *Table S2*). Finally, to handle the expanded feature space after one-hot encoding, we converted the DataFrame into a sparse matrix using SciPy(v1.13.1), enabling efficient model training.

Machine Learning (ML) Pipeline for *In Vitro* Cytotoxicity Predictions. *Model Selection and Implementation.* A diverse array of 18 binary classification algorithms was employed to predict the cytotoxicity of inorganic NPs. These models were implemented by using the SciKit-Learn, CatBoost (v1.2.2), LightGBM (v4.4.0), and XGBoost (v2.0.3) libraries in Python 3.12. To ensure reproducibility, a random state of 3 was set. The suite of algorithms spanned multiple methodological classes, including boosting and tree-based models (such as AdaBoost, gradient boosting classifier, and random forest), clustering algorithms (k-nearest neighbor and radius-neighbor classifiers), discriminant and kernel-based approaches (linear and

quadratic discriminant analysis and support vector classifiers), linear models (logistic regression, perceptron, and stochastic gradient descent), and Naïve–Bayes classifiers. This comprehensive selection allowed for an unbiased evaluation of algorithmic efficacy, ensuring robustness across diverse methodologies. This approach was particularly important given the challenges posed by our dataset, including class imbalance, nonlinear feature interactions, and diverse input feature types. Evaluating a wide range of models also enabled benchmarking against prior nanotoxicity studies using similar ML frameworks.

Training and Internal Testing. Model training was performed on a Lenovo ThinkStation P520 equipped with an Intel Xeon W-2125 CPU and NVIDIA Quadro P4000 GPU, as well as a 2022 Apple MacBook Pro featuring an M2 chip. A 10-fold nested cross-validation (nCV) technique was implemented to ensure robust model evaluation and hyperparameter optimization. In the nCV framework, the outer loop assessed model performance, while the inner loop optimized hyperparameters using the StratifiedKFold, cross_validate, and GridSearchCV functions from the SciKit-Learn library.

The dataset was stratified into 10 folds to maintain a consistent class distribution across folds. During each iteration of the outer loop, nine folds were used for training and one for testing. Hyperparameters were optimized in the inner loop to maximize the area under the precision-recall curve (PR-AUC), a metric well-suited for imbalanced datasets. The list of hyperparameters optimized through grid search is provided in Table S1. Optimal hyperparameters identified from each fold of the inner loop were consolidated into a refined parameter grid, which was subsequently applied to retrain the models on the entire training data partition. This approach enhanced the robustness and generalizability of the final models by focusing on the most effective parameter combinations.

Early stopping was incorporated to prevent overfitting for boosting models (CatBoost, gradient boosting classifier, LightGBM, and XGBoost) that support history monitoring. Log-loss was monitored on a 10% hold-out subset of the training data, with early stopping triggered after 50 consecutive iterations without improvement, up to a maximum of 5,000 boosting rounds. For models that do not employ early stopping, default settings for the number of estimators were used.

To further evaluate model performance, an unseen 20% of the dataset was reserved as an internal test set. The decision threshold was programmatically adjusted using threshold tuning to maximize the F1 score, balancing precision and recall for imbalanced datasets. Evaluation metrics, calculated using the metrics package from SciKit-Learn, included accuracy ($(TP + TN)/(TP + TN + FP + FN)$), ROC-AUC, sensitivity ($TP/(TP + FN)$), specificity ($TN/(TN + FP)$), F1 score ($2 \times ((Precision \times Recall) / (Precision + Recall))$), PR-AUC, Matthews Correlation Coefficient (MCC) ($((TP \times TN) - (FP \times FN)) / (((TP + FP) \times (TP + FN) \times (TN + FP) \times (TN + FN))^{1/2})$), and Balanced Accuracy (BA) score ($((sensitivity + specificity)/2)$).

For the purpose of NP toxicity predictions, true positives (TP) referred to correctly identified toxic NPs, false positives (FP) to nontoxic NPs misclassified as toxic, true negatives (TN) to correctly identified nontoxic NPs, and false negatives (FN) to toxic NPs misclassified as nontoxic. Precision, defined as $TP/(TP + FP)$, measured the proportion of true toxic predictions among all toxic predictions made, while recall (sensitivity), defined as $TP/(TP + FN)$, quantified the proportion of correctly identified toxic NPs among all actual toxic NPs.

Performance metrics such as PR and ROC curves were visualized using the plot() function in Matplotlib (v3.9.1). Given the imbalance in dataset and the high cost associated with false negatives, PR-AUC and recall were prioritized during model evaluation. The five best-performing models were selected based on their robustness in managing class disparity and their effectiveness in minimizing false negatives.

Artificial Neural Network. Neural network models were developed using the Keras-Tuner toolkit (v1.4.7; <https://github.com/keras-team/keras-tuner>) and TensorFlow (v2.10), with TensorFlow Metal

employed for enhanced compatibility with Apple hardware. To ensure consistency across experiments, we implemented a 10-fold nested cross-validation (nCV) framework, mirroring the protocol used for traditional ML models. Four critical hyperparameters—learning rate, number of hidden layers, dropout rate, and type of regularization (L1, L2, or elastic net)—were optimized using Keras-Tuner's GridSearch.

The model architecture followed a sequential design, beginning with an input dense layer containing a number of nodes equal to the feature count of the dataset (Figure S4). Hidden layers, configured based on grid search results, consisted of 128 units each, with RELU activation, batch normalization, and dropout layers applied consistently. Regularization was implemented using L1, L2, or elastic net techniques at a fixed strength of 0.01, enhancing the network's ability to generalize across diverse data. The output layer utilized a sigmoid activation function to generate binary predictions, and the Adam optimizer was selected for its effectiveness in handling sparse gradients and noisy datasets. Binary_crossentropy was employed as the loss function, with PR-AUC as the primary evaluation metric to address the class imbalance of the dataset.

Training included a 10% validation split to monitor binary cross-entropy loss, analogous to log-loss monitoring in traditional ML models. This ensured the early detection of overfitting while maximizing the use of training data. After optimal hyperparameters for each inner fold were identified during nCV, the model was retrained on the full outer training fold before final evaluation on the held-out outer test fold. This systematic optimization and evaluation protocol ensured a thorough assessment of ANN performance with results directly comparable to those from traditional ML models.

Model Unification. To improve the accuracy and robustness of cytotoxicity predictions, we developed a unified model using a stacked ensemble classifier approach implemented with the SciKit-Learn library. This methodology integrates predictions from the five best-performing base models, which were selected based on their PR-AUC and recall performance during cross-validation. A logistic regression metamodel was employed as the stacking layer, enabling an equitable combination of base model outputs while leveraging their diverse predictive strengths. The choice of logistic regression as the meta-learner was motivated by its simplicity and effectiveness in managing multimodel integration without overfitting. Logistic regression operates on the probability outputs of the base models, ensuring smooth integration while maintaining interpretability. This design minimizes bias by distributing reliance across multiple models, improving generalizability, and reducing the risk of overfitting that could arise from dependence on a single predictive model. By combining the unique strengths of individual classifiers, the stacking strategy enhances overall predictive accuracy and addresses the challenges of imbalanced data in NP cytotoxicity predictions. This unified approach ensures that the complementary insights of diverse models are systematically captured, offering a reliable and scalable solution for toxicity assessment.

Explainability Analysis. Global SHAP Ranking. We performed explainability analysis using SHapley Additive exPlanations (SHAP, v0.44)⁶⁰ to establish a global hierarchy of toxicity determinants. SHAP values quantify the contribution of individual features to model predictions, providing insights into their influence on toxicity outcomes. The SHAP value ($\phi_i(f)$) for a feature i is calculated as

$$\phi_i(f) = \sum_{S \subseteq N} \frac{|S|!(|N| - |S| - 1)!}{|N|!} \times [f(S \cup \{i\}) - f(S)]$$

where f is the binary classifier model, S is a subset of all features excluding i , and N is the full-feature set. This equation measures the average impact of including feature i across all feature subsets. SHAP values were computed using the TreeExplainer(output_argument = "probability") function, ensuring interpretations corresponded directly to the probabilistic model outputs.

To simplify interpretation, SHAP values for one-hot encoded categories were aggregated to calculate a single influence score for each feature. This aggregation allowed for direct feature-level comparisons and enhanced interpretability. Beeswarm plots were

generated using the `summary_plot()` function to visualize the distribution of SHAP values with color encoding to represent the magnitude of feature influence. One-hot encoded features were preprocessed using the `encoder` function from SciKit-Learn to facilitate visualization. To assess the consensus of feature rankings across the top five models, we calculated Spearman correlation coefficients using the `corr(method = "spearman")` function from Pandas (v1.1.5). These rankings were visualized as a heatmap generated with the `heatmap()` function in Seaborn (v0.13.2).

Quantifying Structure-Toxicity Relationships. We employed partial dependence plots (PDPs) to evaluate the marginal effects of key continuous variables, i.e., concentration, exposure time, and particle size, on predicted NP toxicity probabilities. PDPs were generated using the `partial_dependence()` function from SciKit-Learn and extended using regression analysis in MATLAB (v2023b) to fit empirical mathematical functions. Confidence intervals (95%) were calculated to quantify the variability. For categorical features, SHAP values were computed separately for each category and filtered to isolate their specific contributions to predicting the toxicity. Non-normal SHAP value distributions were summarized using the median, with positive median SHAP values indicating stronger associations with toxicity predictions and negative values reflecting decreased toxicity likelihoods. These distributions were visualized using boxplots created with Matplotlib and Seaborn.

Feature Reduction. To streamline our best-performing models and improve computational efficiency, we applied an iterative retraining strategy based on feature rankings derived from SHAP analysis. SHAP ranked features by their contribution to toxicity predictions but did not provide a specific cutoff to distinguish crucial features from non-essential ones. Therefore, we progressively incorporated features into the model in descending order of SHAP importance, retraining the model at each step, and monitoring changes in performance metrics, specifically PR-AUC and recall. This iterative approach identified a performance plateau beyond which the inclusion of additional features did not improve PR-AUC or recall, indicating their marginal contribution to toxicity predictions. The results from each iteration were visualized using Matplotlib, highlighting the relationship between feature inclusion and model performance.

Once the minimal subset of features was identified, final retraining phases were conducted on the best-performing models identified earlier (CatBoost, GBC, RF, extra trees, and LightGBM), using only the features deemed crucial. These reduced-feature models were trained and tested using the same nCV and internal testing processes as those described previously to ensure consistency and reliability. Performance comparisons between full- and reduced-feature models were assessed to validate the efficacy of the reduction process.

External Testing for *In Vitro* Cytotoxicity Predictions. To evaluate the generalizability and robustness of our ML models, we conducted external testing using two complementary sources of *in vitro* cytotoxicity data: (1) independent cell viability and hemolysis experiments conducted in-house and (2) supplemental entries from the S²NANO database, a peer-reviewed repository of extensively characterized NPs. Together, these datasets mimic real-world testing conditions and provide a comprehensive framework for validating toxicity predictions. Mesoporous silica nanoparticles (MSNs) were selected as the model nanomaterial for in-house studies, leveraging our team's expertise in synthesizing MSNs with diverse physicochemical properties, including hexagonal and dendritic architectures with tailored size, porosity, and surface functionality.⁷⁵ Lipid and polyethylenimine (PEI) coatings were applied to modulate surface charge and biocompatibility. Detailed descriptions of MSN synthesis, functionalization, characterization, and cytotoxicity assay protocols are provided in the [Supplementary Methods S2](#).

To ensure the broader applicability of our framework, we expanded external testing by incorporating entries from the S²NANO (www.s2nano.org) database, a rigorously curated resource containing NPs across diverse compositions and experimental contexts. The high P-scores assigned to database entries reflect their reliability and quality, sourced through established meta-analyses. This inclusion enabled

testing of model performance on a wide array of NP types, including materials beyond MSNs and across various organ-specific cell lines. All entries were processed using the standardized preprocessing pipeline described earlier, ensuring consistency in feature extraction and toxicity endpoint definitions. Metrics such as PR-AUC, recall, and F1-score confirmed the robustness and predictive accuracy of the ML models across the combined dataset, reinforcing their utility for real-world applications.

Developing an *In Vivo* Nanotoxicity Prediction Framework.

To extend the predictive capabilities of our ML framework to *in vivo* settings, we integrated curated nanotoxicity data with a minimally physiologically based pharmacokinetic (mPBPK) model. This hybrid framework quantifies organ-specific NP exposure, enabling accurate toxicity predictions while accounting for both physiological and physicochemical factors. The approach involves comprehensive data curation, PBPK-based exposure quantification, and retraining the ML framework to enhance its generalizability across diverse preclinical scenarios. Organ-specific exposure metrics, derived from the area under the curve (AUC) of PBPK simulations, replace the concentration feature used *in vitro*, bridging *in vitro* and *in vivo* predictions.

In Vivo Data Curation. To develop robust and generalizable ML models for *in vivo* toxicity, we curated a dataset integrating toxicity and biodistribution data from studies published between January 2004 and May 2024. Data were sourced from Google Scholar, PubMed, and Web of Science. Studies were selected based on stringent inclusion criteria: they utilized murine and rodent models, focused on inorganic NPs with well-defined physicochemical properties (e.g., size, dose, and exposure duration), and employed non-inhalation administration routes (intravenous (IV), subcutaneous (SC), intra-peritoneal (IP), and oral (PO)). Toxicity assessments included biochemical, hematological, or histopathological analyses compared to controls. Only studies reporting NP concentrations in organs at a minimum of three distinct time points were included, enabling accurate PBPK modeling. This rigorous selection process resulted in 35 high-quality studies, forming the foundation for PBPK model development and ML retraining ([Figure 5a](#)).

The final curated dataset consisted of 390 samples, encompassing diverse physicochemical properties and biodistribution patterns. Predominant NP types included gold (42.8%), iron oxide (23.1%), and silver (9.1%), with particle sizes ranging from 1.2 to 310 nm. Surface modifications varied, with poly(ethylene glycol) (PEG) coatings (27.44%) and unmodified NPs (42.05%) representing the majority. IV administration accounted for 90.77% of samples, and key organs, such as the liver (32.05%), kidneys (26.41%), and spleen (16.92%), were most frequently analyzed due to their roles in NP metabolism and clearance.

PBPK Model Development. To simulate NP biodistribution and clearance dynamics *in vivo*, we developed a minimal PBPK model comprising six compartments: plasma, liver, spleen, lungs, kidneys, and others ([Figure 5b](#)). The model accounted for perfusion-limited transport and first-order excretion kinetics, effectively capturing critical pharmacokinetics and transport phenomena ([eqs S1–S8](#)). Time-averaged NP concentrations for individual organs were derived from simulated concentration–time profiles and subsequently used as exposure metrics for ML training. Details on model equations, parametrization, and numerical implementation are provided in [Supplementary Methods S3](#).

Quantifying Organ-Specific NP Biodistribution. Following the parametrization of the PBPK model, the time-averaged concentration (\bar{C}_i) was quantified for each compartment (i) using the equation:

$$\bar{C}_i = \frac{\text{AUC}_i(0 - t_{\text{tox}})}{t_{\text{tox}}}$$

Here, $\text{AUC}_i(0 - t_{\text{tox}})$ represents the area under the PBPK model's concentration–time curve for compartment i up to the time of toxicity measurement (t_{tox}). This time-averaged concentration metric provides a robust summary of NP biodistribution dynamics during the period relevant to toxicity assessments. This approach is particularly

advantageous when comparing studies with varying experimental designs or exposure durations, as it consolidates temporal dynamics into a single representative value. To ensure the reliability of the simulated biodistribution metrics, only model simulations achieving a Pearson correlation coefficient $R > 0.9$ between fitted and observed biodistribution data were included in the final dataset. This threshold criterion ensured the inclusion of only high-confidence simulations for subsequent *in vivo* toxicity prediction modeling.

ML Framework Retraining. To extend the ML framework from *in vitro* to *in vivo* settings, the curated dataset was split into 80% for training and 20% for testing. The same ML pipeline used for *in vitro* data was applied, employing nCV within the training set to optimize hyperparameters and ensure robust model performance. Specifically, a 10-fold nCV approach was implemented to optimize hyperparameters and assess the generalization performance. The outer loop evaluated overall model generalization, while the inner loop fine-tuned hyperparameters for optimal performance. Only the top five performing models from the *in vitro* analysis, along with the stacking ensemble, were retrained to focus on models with demonstrated reliability and predictive power. Additionally, the integration of PBPK-derived time-averaged concentration metrics into the ML framework provided a physiologically meaningful representation of organ-specific NP exposure. This adaptation bridged the gap between *in vitro* and *in vivo* predictions, preserving methodological consistency while accommodating the complexities of *in vivo* dynamics. By concentrating on the most effective models and leveraging PBPK insights, the framework ensured robust and scalable predictions across biological contexts.

ASSOCIATED CONTENT

Data Availability Statement

The data supporting the findings of this study are available from the corresponding author upon reasonable request. The model code is publicly accessible at <https://github.com/prashantdogra17/Nanotoxicity-modeling>.

S Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsnano.5c03590>.

Supplementary methods, figures, and tables: data collection, screening, and curation process (S1); external testing for *in vitro* cytotoxicity predictions (S2); mPBPK model development (S3); overview of the data search, screening, and curation pipeline (Figure S1); loss curves of selected boosting models (Figure S2); PR curves for predictive models using the full-feature set (Figure S3); ROC curves for predictive models using the full-feature set (Figure S4); comparative analysis of optimal ML models versus a simplistic neural network (Figure S5); SHAP interaction plots for continuous NP design features (Figure S6); mPBPK model fits for calculating organ exposures (Figure S7); distribution of fitted mPBPK model parameters across studies (Figure S8); hyperparameters optimized during grid search and their optimal values across models (Table S1); classes excluded in one-hot encoding (Table S2); comprehensive performance metrics of predictive models (Table S3); characterization of mesoporous silica NPs synthesized for external testing (Table S4); list of mPBPK model parameters known a priori (Table S5); list of fitted mPBPK model parameters (Table S6); unit conversions for administered NP dose and organ exposure (Table S7) ([PDF](#))

AUTHOR INFORMATION

Corresponding Author

Prashant Dogra — *Mathematics in Medicine Program, Department of Medicine, Houston Methodist Research Institute, Houston, Texas 77030, United States; Department of Physiology and Biophysics, Weill Cornell Medical College, New York, New York 10065, United States;*  orcid.org/0000-0001-6722-7371; Email: pdogra@houstonmethodist.org

Authors

Joseph Cave — *Mathematics in Medicine Program, Department of Medicine, Houston Methodist Research Institute, Houston, Texas 77030, United States; Physiology, Biophysics, and Systems Biology Program, Graduate School of Medical Sciences, Weill Cornell Medicine, New York, New York 10065, United States*

Anne Christiono — *Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States*

Carmine Schiavone — *Mathematics in Medicine Program, Department of Medicine, Houston Methodist Research Institute, Houston, Texas 77030, United States; Department of Chemical, Materials, and Industrial Production Engineering, University of Naples Federico II, Naples 80138, Italy*

Henry J. Pownall — *Department of Medicine, Houston Methodist, Houston, Texas 77030, United States; Department of Medicine, Weill Cornell Medicine, New York, New York 10065, United States*

Vittorio Cristini — *Mathematics in Medicine Program, Department of Medicine and Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas 77030, United States; Physiology, Biophysics, and Systems Biology Program, Graduate School of Medical Sciences, Weill Cornell Medicine, New York, New York 10065, United States; Department of Imaging Physics, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, United States*

Daniela I. Staquicini — *Rutgers Cancer Institute, Newark, New Jersey 08901, United States; Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School, Newark, New Jersey 08901, United States*

Renata Pasqualini — *Rutgers Cancer Institute, Newark, New Jersey 08901, United States; Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School, Newark, New Jersey 08901, United States*

Wadih Arap — *Rutgers Cancer Institute, Newark, New Jersey 08901, United States; Division of Hematology/Oncology, Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey 08901, United States*

C. Jeffrey Brinker — *Department of Chemical and Biological Engineering, University of New Mexico, Albuquerque, New Mexico 87106, United States;*  orcid.org/0000-0002-7145-9324

Matthew Campen — *College of Pharmacy, University of New Mexico, Albuquerque, New Mexico 87106, United States*

Zhihui Wang — *Mathematics in Medicine Program, Department of Medicine and Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas 77030, United States; Department of Physiology and Biophysics, Weill Cornell Medical College, New York, New York 10065, United States;*  orcid.org/0000-0001-6262-700X

Hien Van Nguyen – Department of Electrical and Computer Engineering, University of Houston, Houston, Texas 77204, United States

Achraf Noureddine – Department of Chemical and Biological Engineering, University of New Mexico, Albuquerque, New Mexico 87106, United States;  orcid.org/0000-0001-9530-5963

Complete contact information is available at:
<https://pubs.acs.org/10.1021/acsnano.5c03590>

Author Contributions

P.D. conceived the study. JC, PD, and AC designed the ML pipeline. JC, AC, and CS performed the ML analyses. PD developed the PBPK model, and JC and CS performed the PBPK analysis. AN performed *in vitro* cytotoxicity experiments. JC, PD, AN, HJP, ZW, VC, DIS, RP, WA, CJB, MC, and HVN interpreted the biological relevance of the findings. JC, PD, and AN wrote the manuscript, with editing contributions from AC, CS, HJP, ZW, VC, DIS, RP, WA, CJB, MC, and HVN.

Notes

The authors declare the following competing financial interest(s): RP and WA are founders and equity shareholders of PhageNova Bio. RP is the Chief Scientific Officer and serves as a paid consultant for PhageNova Bio. RP and WA are founders and equity shareholders of and serve as paid consultants for MBrace Therapeutics. RP and WA have sponsored research agreements in place with both PhageNova Bio and MBrace Therapeutics. The other authors declare that no conflicts of interest exist.

ACKNOWLEDGMENTS

This research work was supported in part by the National Institutes of Health (NIH) Grants 1R01EB035545 (P.D. and A.N.) and 1R01CA253865 (Z.W.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors thank Madison Parrot, Dr. Maria J. Peláez, and Aarush Tutiki for their assistance with data extraction from the literature. All figures and schematics, including those created with BioRender (www.biorender.com), were prepared by the authors, with feedback provided by Kate Proctor.

REFERENCES

- (1) Luther, D. C.; Huang, R.; Jeon, T.; Zhang, X.; Lee, Y. W.; Nagaraj, H.; Rotello, V. M. Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles. *Adv. Drug Deliv Rev.* **2020**, *156*, 188–213.
- (2) Mitchell, M. J.; Billingsley, M. M.; Haley, R. M.; Wechsler, M. E.; Peppas, N. A.; Langer, R. Engineering precision nanoparticles for drug delivery. *Nat. Rev. Drug Discovery* **2021**, *20* (2), 101–124.
- (3) Dong, E.; Huo, Q.; Zhang, J.; Han, H.; Cai, T.; Liu, D. Advancements in nanoscale delivery systems: optimizing intermolecular interactions for superior drug encapsulation and precision release. *Drug Delivery and Translational Research* **2025**, *15* (1), 7–25.
- (4) da Cruz Schneid, A.; Albuquerque, L. J. C.; Mondo, G. B.; Ceolin, M.; Picco, A. S.; Cardoso, M. B. Colloidal stability and degradability of silica nanoparticles in biological fluids: a review. *J. Sol-Gel Sci. Technol.* **2022**, *102* (1), 41–62.
- (5) Sanna, V.; Sechi, M. Therapeutic Potential of Targeted Nanoparticles and Perspective on Nanotherapies. *ACS Med. Chem. Lett.* **2020**, *11* (6), 1069–1073.
- (6) Unnikrishnan, G.; Joy, A.; Megha, M.; Kolanthai, E.; Senthilkumar, M. Exploration of inorganic nanoparticles for revolutionary drug delivery applications: a critical review. *Discover Nano* **2023**, *18* (1), 157.
- (7) Xue, C.; Hu, S.; Gao, Z.-H.; Wang, L.; Luo, M.-X.; Yu, X.; Li, B.-F.; Shen, Z.; Wu, Z.-S. Programmably tiling rigidified DNA brick on gold nanoparticle as multi-functional shell for cancer-targeted delivery of siRNAs. *Nat. Commun.* **2021**, *12* (1), 2928.
- (8) Ming, J.; Chen, Y.; Miao, H.; Fan, Y.; Wang, S.; Chen, Z.; Guo, Z.; Guo, Z.; Qi, L.; Wang, X.; et al. High-brightness transition metal-sensitized lanthanide near-infrared luminescent nanoparticles. *Nat. Photonics* **2024**, *18* (12), 1254–1262.
- (9) Xu, P.; Zhong, S.; Wei, Y.; Duan, X.; Zhang, M.; Shen, W.; Ma, Y.; Zhang, Y.-H. Surface-Functionalized Halo-Tag Gold Nanoprobes for Live-Cell Long-Term Super-Resolution Imaging of Endoplasmic Reticulum Dynamics. *ACS Nano* **2024**, *18* (32), 21433–21446.
- (10) Zhang, J.; Liu, Z.; Zhang, Z.; Yang, H.; Wang, H.; Yang, Z.; Xu, Y.; Li, S.; Yang, D. Recent Advances in Silica-Based Nanomaterials for Enhanced Tumor Imaging and Therapy. *ACS Applied Bio Materials* **2024**, *7* (11), 7133–7169.
- (11) Tsikourkitoudi, V.; Henriques-Normark, B.; Sotiriou, G. A. Inorganic nanoparticle engineering against bacterial infections. *Current Opinion in Chemical Engineering* **2022**, *38*, No. 100872.
- (12) Li, G.; Wang, C.; Jin, B.; Sun, T.; Sun, K.; Wang, S.; Fan, Z. Advances in smart nanotechnology-supported photodynamic therapy for cancer. *Cell Death Discovery* **2024**, *10* (1), 466.
- (13) Zhou, W.; Hu, K.; Kwee, S.; Tang, L.; Wang, Z.; Xia, J.; Li, X. Gold Nanoparticle Aggregation-Induced Quantitative Photothermal Biosensing Using a Thermometer: A Simple and Universal Biosensing Platform. *Anal. Chem.* **2020**, *92* (3), 2739–2747.
- (14) Cai, J.; Peng, J.; Feng, J.; Li, R.; Ren, P.; Zang, X.; Wu, Z.; Lu, Y.; Luo, L.; Hu, Z.; et al. Antioxidant hepatic lipid metabolism can be promoted by orally administered inorganic nanoparticles. *Nat. Commun.* **2023**, *14* (1), 3643.
- (15) Shakeri-Zadeh, A.; Bulte, J. W. M. Imaging-guided precision hyperthermia with magnetic nanoparticles. *Nat. Rev. Bioeng.* **2025**, *3*, 245.
- (16) Abrishami, A.; Bahrami, A. R.; Nekooei, S.; Saljooghi, A.; Matin, M. M. Hybridized quantum dot, silica, and gold nanoparticles for targeted chemo-radiotherapy in colorectal cancer theranostics. *Commun. Biol.* **2024**, *7* (1), 393.
- (17) Anselmo, A. C.; Mitragotri, S. Nanoparticles in the clinic: An update post COVID-19 vaccines. *Bioengineering & Translational Medicine* **2021**, *6* (3), No. e10246.
- (18) Wang, Y.; Cai, R.; Chen, C. The Nano–Bio Interactions of Nanomedicines: Understanding the Biochemical Driving Forces and Redox Reactions. *Acc. Chem. Res.* **2019**, *52* (6), 1507–1518.
- (19) Zelepukin, I. V.; Shevchenko, K. G.; Deyev, S. M. Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery. *Nat. Commun.* **2024**, *15* (1), 4366.
- (20) Tsoi, K. M.; MacParland, S. A.; Ma, X. Z.; Spetzler, V. N.; Echeverri, J.; Ouyang, B.; Fadel, S. M.; Sykes, E. A.; Goldaracena, N.; Kath, J. M.; Conneely, J. B.; Alman, B. A.; Selzner, M.; Ostrowski, M. A.; Adeyi, O. A.; Zilman, A.; McGilvray, I. D.; Chan, W. C. W. Mechanism of hard-nanomaterial clearance by the liver. *Nat. Mater.* **2016**, *15* (11), 1212–1221.
- (21) Chen, Q.; Yuan, L.; Chou, W.-C.; Cheng, Y.-H.; He, C.; Monteiro-Riviere, N. A.; Riviere, J. E.; Lin, Z. Meta-Analysis of Nanoparticle Distribution in Tumors and Major Organs in Tumor-Bearing Mice. *ACS Nano* **2023**, *17* (20), 19810–19831.
- (22) Wilhelm, S.; Tavares, A. J.; Dai, Q.; Ohta, S.; Audet, J.; Dvorak, H. F.; Chan, W. C. W. Analysis of nanoparticle delivery to tumours. *Nat. Rev. Mater.* **2016**, *1* (5), 1–12.
- (23) Olugbodi, J. O.; Lawal, B.; Bako, G.; Onikanni, A. S.; Abolenin, S. M.; Mohammad, S. S.; Ataya, F. S.; Batiha, G. E.-S. Effect of subdermal exposure of silver nanoparticles on hepatic, renal and cardiac functions accompanying oxidative damage in male Wistar rats. *Sci. Rep.* **2023**, *13* (1), 10539.
- (24) Li, X.; Wang, B.; Zhou, S.; Chen, W.; Chen, H.; Liang, S.; Zheng, L.; Yu, H.; Chu, R.; Wang, M.; et al. Surface chemistry governs the sub-organ transfer, clearance and toxicity of functional gold

- nanoparticles in the liver and kidney. *J. Nanobiotechnol.* **2020**, *18* (1), 45.
- (25) Xuan, L.; Ju, Z.; Skonieczna, M.; Zhou, P.-K.; Huang, R. Nanoparticles-induced potential toxicity on human health: Applications, toxicity mechanisms, and evaluation models. *MedComm* **2023**, *4* (4), No. e327.
- (26) Mohammadpour, R.; Dobrovolskaia, M. A.; Cheney, D. L.; Greish, K. F.; Ghandehari, H. Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications. *Adv. Drug Deliv. Rev.* **2019**, *144*, 112–132.
- (27) Zelepukin, I. V.; Yaremenko, A. V.; Yuryev, M. V.; Mirkasymov, A. B.; Sokolov, I. L.; Deyev, S. M.; Nikitin, P. I.; Nikitin, M. P. Fast processes of nanoparticle blood clearance: Comprehensive study. *J. Controlled Release* **2020**, *326*, 181–191.
- (28) Kumar, M.; Kulkarni, P.; Liu, S.; Chemuturi, N.; Shah, D. K. Nanoparticle biodistribution coefficients: A quantitative approach for understanding the tissue distribution of nanoparticles. *Adv. Drug Delivery Rev.* **2023**, *194*, No. 114708.
- (29) Havelikar, U.; Ghorpade, K. B.; Kumar, A.; Patel, A.; Singh, M.; Banjare, N.; Gupta, P. N. Comprehensive insights into mechanism of nanotoxicity, assessment methods and regulatory challenges of nanomedicines. *Discover Nano* **2024**, *19* (1), 165.
- (30) Egbuna, C.; Parmar, V. K.; Jeevanandam, J.; Ezzat, S. M.; Patrick-Iwuanyanwu, K. C.; Adetunji, C. O.; Khan, J.; Onyeike, E. N.; Uche, C. Z.; Akram, M.; et al. Toxicity of Nanoparticles in Biomedical Application: Nanotoxicology. *J. Toxicol.* **2021**, *2021* (1), No. 9954443.
- (31) Dogra, P.; Adolphi, N. L.; Wang, Z.; Lin, Y.-S.; Butler, K. S.; Durfee, P. N.; Croissant, J. G.; Noureddine, A.; Coker, E. N.; Bearer, E. L.; et al. Establishing the effects of mesoporous silica nanoparticle properties on in vivo disposition using imaging-based pharmacokinetics. *Nat. Commun.* **2018**, *9* (1), 4551.
- (32) Yu, Z.; Li, Q.; Wang, J.; Yu, Y.; Wang, Y.; Zhou, Q.; Li, P. Reactive Oxygen Species-Related Nanoparticle Toxicity in the Biomedical Field. *Nanoscale Res. Lett.* **2020**, *15* (1), 115.
- (33) Shukla, R. K.; Badiye, A.; Vajpayee, K.; Kapoor, N. Genotoxic Potential of Nanoparticles: Structural and Functional Modifications in DNA. *Front. Genet.* **2021**, *12*, No. 728250.
- (34) Foreman-Ortiz, I. U.; Liang, D.; Laudadio, E. D.; Calderin, J. D.; Wu, M.; Keshri, P.; Zhang, X.; Schwartz, M. P.; Hamers, R. J.; Rotello, V. M.; et al. Anionic nanoparticle-induced perturbation to phospholipid membranes affects ion channel function. *Proc. Natl. Acad. Sci. U. S. A.* **2020**, *117* (45), 27854–27861.
- (35) Jia, X.; Wang, S.; Zhou, L.; Sun, L. The Potential Liver, Brain, and Embryo Toxicity of Titanium Dioxide Nanoparticles on Mice. *Nanoscale Res. Lett.* **2017**, *12* (1), 478.
- (36) Mohammadpour, R.; Ghandehari, H. Mechanisms of immune response to inorganic nanoparticles and their degradation products. *Adv. Drug Delivery Rev.* **2022**, *180*, No. 114022.
- (37) Li, J.; Wang, C.; Yue, L.; Chen, F.; Cao, X.; Wang, Z. Nano-QSAR modeling for predicting the cytotoxicity of metallic and metal oxide nanoparticles: A review. *Ecotoxicology and Environmental Safety* **2022**, *243*, No. 113955.
- (38) Martin; Watanabe, R.; Hashimoto, K.; Higashisaka, K.; Haga, Y.; Tsutsumi, Y.; Mizuguchi, K. Evidence-Based Prediction of Cellular Toxicity for Amorphous Silica Nanoparticles. *ACS Nano* **2023**, *17* (11), 9987–9999.
- (39) Labouta, H. I.; Asgarian, N.; Rinker, K.; Cramb, D. T. Meta-Analysis of Nanoparticle Cytotoxicity via Data-Mining the Literature. *ACS Nano* **2019**, *13* (2), 1583–1594.
- (40) Masarkar, A.; Maparu, A. K.; Nukavarapu, Y. S.; Rai, B. Predicting Cytotoxicity of Nanoparticles: A Meta-Analysis Using Machine Learning. *ACS Applied Nano Materials* **2024**, *7* (17), 19991–20002.
- (41) Yu, F.; Wei, C.; Deng, P.; Peng, T.; Hu, X. Deep exploration of random forest model boosts the interpretability of machine learning studies of complicated immune responses and lung burden of nanoparticles. *Science. Advances* **2021**, *7* (22), No. eabf4130.
- (42) Meneses, J.; González-Durruthy, M.; Fernandez-de-Gortari, E.; Toropova, A. P.; Toropov, A. A.; Alfaro-Moreno, E. A Nano-QSTR model to predict nano-cytotoxicity: an approach using human lung cells data. *Part. Fibre Toxicol.* **2023**, *20* (1), 21.
- (43) Ahmadi, M.; Ayyoubzadeh, S. M.; Ghorbani-Bidkorpeh, F. Toxicity prediction of nanoparticles using machine learning approaches. *Toxicology* **2024**, *501*, No. 153697.
- (44) Luan, F.; Kleandrova, V. V.; González-Díaz, H.; Russo, J. M.; Melo, A.; Speck-Planche, A.; Cordeiro, M. N. D. S. Computer-aided nanotoxicology: assessing cytotoxicity of nanoparticles under diverse experimental conditions by using a novel QSTR-perturbation approach. *Nanoscale* **2014**, *6* (18), 10623–10630.
- (45) Concu, R.; Kleandrova, V. V.; Speck-Planche, A.; Cordeiro, M. N. D. S. Probing the toxicity of nanoparticles: a unified in silico machine learning model based on perturbation theory. *Nanotoxicology* **2017**, *11* (7), 891–906.
- (46) He, S.; Nader, K.; Abarrategi, J. S.; Bediaga, H.; Nocedo-Mena, D.; Ascencio, E.; Casanola-Martin, G. M.; Castellanos-Rubio, I.; Insausti, M.; Rasulev, B.; et al. NANO.PTML model for read-across prediction of nanosystems in neurosciences. computational model and experimental case of study. *J. Nanobiotechnol.* **2024**, *22* (1), 435.
- (47) Toropova, A. P.; Toropov, A. A. Nano-QSAR in cell biology: Model of cell viability as a mathematical function of available eclectic data. *J. Theor. Biol.* **2017**, *416*, 113–118.
- (48) Toropov, A. A.; Toropova, A. P. QSPR/QSAR: State-of-Art, Weirdness, the Future. *Molecules* **2020**, *25* (6), 1292.
- (49) Ambure, P.; Halder, A. K.; González Díaz, H.; Cordeiro, M. N. D. S. QSAR-Co: An Open Source Software for Developing Robust Multitasking or Multitarget Classification-Based QSAR Models. *J. Chem. Inf. Model.* **2019**, *59* (6), 2538–2544.
- (50) Halder, A. K.; Dias Soeiro Cordeiro, M. N. QSAR-Co-X: an open source toolkit for multitarget QSAR modelling. *Journal of Cheminformatics* **2021**, *13* (1), 29.
- (51) Furxhi, I.; Murphy, F.; Poland, C. A.; Sheehan, B.; Mullins, M.; Manteca, P. Application of Bayesian networks in determining nanoparticle-induced cellular outcomes using transcriptomics. *Nanotoxicology* **2019**, *13* (6), 827–848.
- (52) Bilgi, E.; Karakus, C. O. Machine learning-assisted prediction of the toxicity of silver nanoparticles: a meta-analysis. *J. Nanopart. Res.* **2023**, *25*, 157.
- (53) Kad, A.; Pundir, A.; Arya, S. K.; Puri, S.; Khatri, M. Meta-analysis of in-vitro cytotoxicity evaluation studies of zinc oxide nanoparticles: Paving way for safer innovations. *Toxicology in Vitro* **2022**, *83*, No. 105418.
- (54) Huang, Y.; Li, X.; Cao, J.; Wei, X.; Li, Y.; Wang, Z.; Cai, X.; Li, R.; Chen, J. Use of dissociation degree in lysosomes to predict metal oxide nanoparticle toxicity in immune cells: Machine learning boosts nano-safety assessment. *Environ. Int.* **2022**, *164*, No. 107258.
- (55) Choi, J.-S.; Ha, M. K.; Trinh, T. X.; Yoon, T. H.; Byun, H.-G. Towards a generalized toxicity prediction model for oxide nanomaterials using integrated data from different sources. *Sci. Rep.* **2018**, *8* (1), 6110.
- (56) Bertagnolli, M. M. *Statement on catalyzing the development of novel alternative methods*. National Institutes of Health, 2024. <https://www.nih.gov/about-nih/who-we-are/nih-director/statements/statement-catalyzing-development-novel-alternatives-methods> (accessed 2024).
- (57) Gul, G.; Yildirim, R.; Ileri-Ercan, N. Cytotoxicity analysis of nanoparticles by association rule mining. *Environmental Science: Nano* **2021**, *8* (4), 937–949.
- (58) Araf, I.; Idri, A.; Chairi, I. Cost-sensitive learning for imbalanced medical data: a review. *Artificial Intelligence Review* **2024**, *57* (4), 80.
- (59) Branco, P.; Torgo, L.; Ribeiro, R. P.; et al. A Survey of Predictive Modeling on Imbalanced Domains. *ACM Comput. Surv.* **2016**, *49* (2), 1–50.
- (60) Lundberg, S. M.; Lee, S.-I. A unified approach to interpreting model predictions. In *Proceedings of the 31st International Conference*

- on Neural Information Processing Systems, Curran Associates Inc.: Long Beach, California, USA, 2017.
- (61) Weiss, M.; Fan, J.; Claudel, M.; Sonntag, T.; Didier, P.; Ronzani, C.; Lebeau, L.; Pons, F. Density of surface charge is a more predictive factor of the toxicity of cationic carbon nanoparticles than zeta potential. *J. Nanobiotechnol.* **2021**, *19* (1), S.
- (62) Lee, J. H.; Ju, J. E.; Kim, B. I.; Pak, P. J.; Choi, E.-K.; Lee, H.-S.; Chung, N. Rod-shaped iron oxide nanoparticles are more toxic than sphere-shaped nanoparticles to murine macrophage cells. *Environ. Toxicol. Chem.* **2014**, *33* (12), 2759–2766.
- (63) Song, H. N.; Jang, S. K.; Hwang, O. K.; Lee, H. J.; Chun, H. S. TiO₂ particles induce ER stress and apoptosis in human hepatoma cells, HepG2, in a particle size-dependent manner. *Food Sci. Biotechnol.* **2019**, *28* (6), 1907–1917.
- (64) Pan, Y.; Neuss, S.; Leifert, A.; Fischler, M.; Wen, F.; Simon, U.; Schmid, G.; Brandau, W.; Jahnens-Decent, W. Size-Dependent Cytotoxicity of Gold Nanoparticles. *Small* **2007**, *3* (11), 1941–1949.
- (65) Tang, D.; Cui, M.; Wang, B.; Liang, G.; Zhang, H.; Xiao, H. Nanoparticles destabilizing the cell membranes triggered by NIR light for cancer imaging and photo-immunotherapy. *Nat. Commun.* **2024**, *15* (1), 6026.
- (66) Sukhanova, A.; Bozrova, S.; Sokolov, P.; Berestovoy, M.; Karaulov, A.; Nabiev, I. Dependence of Nanoparticle Toxicity on Their Physical and Chemical Properties. *Nanoscale Res. Lett.* **2018**, *13* (1), 44.
- (67) Shao, X.-R.; Wei, X.-Q.; Song, X.; Hao, L.-Y.; Cai, X.-X.; Zhang, Z.-R.; Peng, Q.; Lin, Y.-F. Independent effect of polymeric nanoparticle zeta potential/surface charge, on their cytotoxicity and affinity to cells. *Cell Proliferation* **2015**, *48* (4), 465–474.
- (68) Hühn, D.; Kantner, K.; Geidel, C.; Brandholt, S.; De Cock, I.; Soenen, S. J. H.; Rivera_Gil, P.; Montenegro, J.-M.; Braeckmans, K.; Müllen, K.; et al. Polymer-Coated Nanoparticles Interacting with Proteins and Cells: Focusing on the Sign of the Net Charge. *ACS Nano* **2013**, *7* (4), 3253–3263.
- (69) Kobayashi, J.; Kizu, R.; Sugiyama, H. Influences of Polyaromatic Hydrocarbons and Heavy Metals on a Thyroid Carcinoma Cell Line. *J. Health Sci.* **2005**, *51*, 202–206.
- (70) Ramasamy, M.; Das, M.; An, S. S.; Yi, D. K. Role of surface modification in zinc oxide nanoparticles and its toxicity assessment toward human dermal fibroblast cells. *Int. J. Nanomedicine* **2014**, *9*, 3707–3718.
- (71) Foldbjerg, R.; Olesen, P.; Hougaard, M.; Dang, D. A.; Hoffmann, H. J.; Autrup, H. PVP-coated silver nanoparticles and silver ions induce reactive oxygen species, apoptosis and necrosis in THP-1 monocytes. *Toxicol. Lett.* **2009**, *190* (2), 156–162.
- (72) Bhattacharjee, S.; de Haan, L. H. J.; Evers, N. M.; Jiang, X.; Marcelis, A. T. M.; Zuilhof, H.; Rietjens, I. M. C. M.; Alink, G. M. Role of surface charge and oxidative stress in cytotoxicity of organic monolayer-coated silicon nanoparticles towards macrophage NR8383 cells. *Particle and Fibre Toxicology* **2010**, *7* (1), 25.
- (73) Yang, H.; Liu, C.; Yang, D.; Zhang, H.; Xi, Z. Comparative study of cytotoxicity, oxidative stress and genotoxicity induced by four typical nanomaterials: the role of particle size, shape and composition. *J. Appl. Toxicol.* **2009**, *29* (1), 69–78.
- (74) Wu, L.; Wen, W.; Wang, X.; Huang, D.; Cao, J.; Qi, X.; Shen, S. Ultrasmall iron oxide nanoparticles cause significant toxicity by specifically inducing acute oxidative stress to multiple organs. *Particle and Fibre Toxicology* **2022**, *19* (1), 24.
- (75) Noureddine, A.; Maestas-Olguin, A.; Tang, L.; Corman-Hijar, J. I.; Olewine, M.; Krawchuck, J. A.; Tsala Ebode, J.; Edeh, C.; Dang, C.; Negrete, O. A.; et al. Future of Mesoporous Silica Nanoparticles in Nanomedicine: Protocol for Reproducible Synthesis, Characterization, Lipid Coating, and Loading of Therapeutics (Chemotherapeutic, Proteins, siRNA and mRNA). *ACS Nano* **2023**, *17* (17), 16308–16325.
- (76) Marwedel, B.; De May, H.; Anderson, L.; Medina, L. Y.; Kennedy, E.; Flores, E.; O'Rourke, J.; Olewine, M.; Lagutina, I.; Fitzpatrick, L.; et al. TLR Agonist Nano Immune Therapy Clears Peritoneal and Systemic Ovarian Cancer. *Adv. Healthcare Mater.* **2025**, *14*, No. 2402966.
- (77) Zhang, D.; Tang, L.; Hipple, T.; Mowry, C. D.; Brinker, C. J.; Brey, E.; Noureddine, A.; Gonzalez Porras, M. A. Local Administration of Lipid-Silica Nanohybrid-Carried Forskolin Modulates Thermogenesis in Human Adipocytes and Impedes Weight Gain in Mice. *Adv. Funct. Mater.* **2024**, *35*, No. 2404179.
- (78) Parrot, M.; Cave, J.; Pelaez, M. J.; Ghandehari, H.; Dogra, P.; Yellepeddi, V. A Minimal PBPK Model Describes the Differential Disposition of Silica Nanoparticles In Vivo. *medRxiv* **2024**, 2024.09.2018.24313941. DOI: .
- (79) Dogra, P.; Butner, J. D.; Ruiz Ramírez, J.; Chuang, Y. I.; Noureddine, A.; Jeffrey Brinker, C.; Cristini, V.; Wang, Z. A mathematical model to predict nanomedicine pharmacokinetics and tumor delivery. *Comput. Struct. Biotechnol. J.* **2020**, *18*, 518–531.
- (80) Goel, S.; Ferreira, C. A.; Dogra, P.; Yu, B.; Kutyreff, C. J.; Siamof, C. M.; Engle, J. W.; Barnhart, T. E.; Cristini, V.; Wang, Z.; Cai, W. Size-Optimized Ultrasmall Porous Silica Nanoparticles Depict Vasculature-Based Differential Targeting in Triple Negative Breast Cancer. *Small* **2019**, No. 1903747.
- (81) Dogra, P.; Butner, J. D.; Chuang, Y.-I.; Caserta, S.; Goel, S.; Brinker, C. J.; Cristini, V.; Wang, Z. Mathematical modeling in cancer nanomedicine: a review. *Biomed. Microdevices* **2019**, *21* (2), 40.
- (82) Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans. *Pharm. Res.* **1993**, *10* (7), 1093–1095.